CD8A and neoplasm: Furthermore, developing small molecule inhibitors targeting BCAA transporters in tumor cells and immunosuppressive cells allows CD8+ T cells to obtain amino acid metabolic advantages in the immune microenvironment and enhance the anti-tumor effect.